Persistence of treatment with 5-grass pollen tablets in patients with allergic rhinitis: a real-life study

Ras, Liesbeth; Groot, Hans de; Stengs, Cornelis H.M.; Weissenbruch, Ranny van

doi:10.1016/j.anai.2015.10.018

Cited by 6 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with this finding, all enrolled patients completed at least three years of treatment, showing 100% spontaneous adherence to the prescribed treatment. Contrary to other studies in which a high treatment adherence was obtained thanks to the help of nurse interventions, frequent scheduled visits and telephone calls [17][18][19], herein, our patients showed 100% spontaneousadherence to the prescribed treatment. In this regard, we believe that patients were obtaining real benefit from the treatment probably since the first year of the therapy; thus, a good efficacy achieved during the first year of treatment could be considered as a favourable prognostic factor for treatment adherence for the next two years with long-lasting positive effects in real-practice.…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Efficacy and perceived satisfaction of 3-year SLIT in children with allergic rhinitis and asthma: A pilot study in real-life .

Manti

Tropea

Ledda

et al. 2022

Preprint

View full text Add to dashboard Cite

Background. Despite the presence of robust evidence, very sparse data are available on the efficacy of allergen immunotherapy (AIT) on selected patients in real-life. Moreover, the obtained data does not ever fit with the general population; thus, the translation and the use of data obtained from randomized clinical trials (RCTs) in real-practice can be questionable. Accordingly, we aimed to evaluate in real-life efficacy and perceived satisfaction of 3-year sublingual immunotherapy (SLIT) in a pediatric population with with allergic rhinitis and/or asthma. Methods. A pilot, monocenter, retrospective cohort, real-life study was performed. 153 children who fulfilled the criteria for allergic rhinitis and asthma and mono- or poly-sensitized were enrolled. A standardized questionnaire on perceived efficacy, rescue medication, disease control, number of exacerbations, quality of life, and perceived satisfaction was administered to each patient. Results. 70 patients (49 males, 21 females; mean age, 14.3±1.9 years) were included in the final analysis. All 70 patients received SLIT for up to three years, with 100% treatment adherence throughout the study duration. Significant improvement in symptoms and quality of life was reported (p<0.01). A significant decrease in disease severity, rescue medication use, and sleep disturbances was reported (p<0.01). A significant improvement was also recorded in school performance (p<0.01). 60/70 (85.7%) of all enrolled patients declared themselves very satisfied, 6/70 (8.57%) much satisfied, and 4/60 (5.71%) satisfied. Conclusions. We firstly showed the efficacy and perceived satisfaction of 3-year SLIT in a paediatric population, with 100% treatment adherence throughout the study duration, in real-life.

show abstract

Section: Discussioncontrasting

confidence: 99%

“…Globally, we evaluated 70 patients (49 males, 21 females; mean (SD) age, 14.3 ± 1.9 years; age range [10][11][12][13][14][15][16][17][18]. The patients' demographic and clinical characteristics and sensitization are reported in Table 1.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and perceived satisfaction of 3-year SLIT in children with allergic rhinitis and asthma: A pilot study in real-life .

Manti

Tropea

Ledda

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“… German 1-y prospective, open-label, observational study Schafer et al 56 Adults (≥18 y) with moderate-severe ARC ± mild asthma (n=327) Significant improvements in ARC symptoms and reduction in medication use; improved QoL and treatment satisfaction. Netherlands prospective, open-label, observational study over 1 season Ras et al 57 Children and adults (≥5 years) with moderate-severe ARC ± mild asthma (n=196) Reduction in frequency and severity of ARC symptoms; high persistence with treatment (70%) and intention to continue the following season (80%). Italian prospective, open-label, observational study over 1 season Pastorello et al 58 Children and adults (12–45 y) with mild/moderate-severe ARC ± mild asthma (n=47) Reduction in symptom severity and medication use.…”

Section: Efficacy and Safety Of Oralair® In Allergic Rhinitismentioning

confidence: 99%

“… 53 Another German study reported that compliance rated highly over 1 y, 56 while in the Netherlands, persistence with treatment was 85% after 1 month and 70% after 7 months. 57 Most recently a large German multicentre observational study evaluated Oralair® use over one season in 883 children, adolescents, and adults with AR, many of whom were polyallergic; outcomes were measured using a validated ‘Patient Benefit Index—Allergic Rhinitis (PBI-AR) score. Clinically relevant benefit was reported in 89–95% of subjects in all age-groups; in adolescents and adults, higher benefit was reported in polyallergic subjects than in monoallergic subjects.…”

Section: Efficacy and Safety Of Oralair® In Allergic Rhinitismentioning

confidence: 99%

Update about Oralair® as a treatment for grass pollen allergic rhinitis

Klimek

Mösges

Demoly

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Sublingual immunotherapy (SLIT) is a well-tolerated, safe, and effective approach to treating allergic rhinitis (AR). Oralair® is a five-grass pollen SLIT tablet containing natural pollen allergens from five of the major grass species responsible for seasonal AR due to grass pollen allergy. Recommended use is in a pre-coseasonal regimen, starting daily treatment approximately 4 months before the start of the pollen season, with treatment then continued daily throughout the season; treatment should continue for 3–5 y. Clinical efficacy and safety of Oralair® in patients with grass pollen-induced AR has been demonstrated in a comprehensive clinical development program of randomized controlled trials. Effectiveness has been substantiated in subsequent observational studies with sustained efficacy following treatment cessation and a favorable level of adherence, quality of life, benefit, and satisfaction for the patients. Supportive evidence for a benefit in reducing the risk or delaying the development of allergic asthma is emerging.

show abstract

“…Reported participants' ages ranged from 2 to 76 years. Five studies (15.6%) enrolled adults only, [26][27][28][29][30] 22 (68.8%) both adults and children, 15,16,[18][19][20]22,[31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46] and five (15.6%) children only (<18 years of age, n = 5471 participants) 14,17,21,47,48 (Figure 2). Studies were conducted in Germany (n = 6); Italy (n = 5); the United Stated and South Korea (n = 3); Sweden, Denmark, France, China, Spain, Netherlands, and Japan (n = 2); and Kuwait and the United Kingdom (n = 1).…”

Section: Resultsmentioning

confidence: 99%

Sublingual immunotherapy persistence and adherence in real‐world settings: A systematic review

Park

Kapoor

et al. 2022

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background Sublingual immunotherapy (SLIT) adherence in the literature is often evaluated in closely monitored trials that may impact patient behavior; real‐world SLIT adherence is relatively unknown. This systematic review intends to assess SLIT adherence in studies that reflect real‐world settings. Methods A literature search of PubMed, Embase, Cochrane, Web of Science, and Scopus for real‐world studies examining SLIT adherence was performed. Monitored clinical trials were excluded. Paired investigators independently reviewed all articles. For this review, “persistence” was defined as continuing therapy and not being lost to follow‐up and “adherence” as persistence in accordance with prescribed SLIT dose, dosing schedule, and duration. Article quality was assessed using a modified Newcastle–Ottawa scale and then converted to AHRQ standards (good, fair, and poor). Results The search yielded 1596 nonduplicate abstracts, from which 32 articles (n = 63,683 patients) met criteria. Twenty‐six (81%) studies reported persistence rates ranging from 7.0% to 88.7%, and 18 (56%) reported adherence rates ranging from 9.6% to 97.0%. Twenty‐one (66%) studies surveyed reasons for discontinuing SLIT. All studies were Oxford level of evidence 2b and of good (n = 12) to fair (n = 20) quality. Conclusion Reported rates of real‐world SLIT persistence and adherence varied widely by study methodology (e.g., follow‐up duration, objective vs. subjective assessment). Studies with longer follow‐up generally reported lower rates; 3‐year persistence ranged from 7% to 59.0% and 3‐year adherence from 9.6% to 49.0%. Future studies of SLIT adherence would benefit from following concordant definitions of persistence/adherence and standardized reporting metrics.

show abstract

Persistence of treatment with 5-grass pollen tablets in patients with allergic rhinitis: a real-life study

Cited by 6 publications

References 36 publications

Efficacy and perceived satisfaction of 3-year SLIT in children with allergic rhinitis and asthma: A pilot study in real-life .

Efficacy and perceived satisfaction of 3-year SLIT in children with allergic rhinitis and asthma: A pilot study in real-life .

Update about Oralair® as a treatment for grass pollen allergic rhinitis

Sublingual immunotherapy persistence and adherence in real‐world settings: A systematic review

Contact Info

Product

Resources

About